GlassScriptPhysician profile
Jeffrey Wuhl
NPI 1740421346
$16,531.92
in general payments reported to CMS, 2019-2025
20 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $429 · 2021: $222 · 2022: $319 · 2023: $689 · 2024: $951 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,321.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,693.06 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Janssen Pharmaceuticals, INC | $731.01 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $535.57 | 2023-2025 | Optimizer, Optimizer |
| Novo Nordisk INC | $338.49 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $324.58 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $146.79 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $126.60 | 2019-2020 | |
| Heartflow, INC. | $110.95 | 2022-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $102.85 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.25 | 2019-2020 | |
| Amarin Pharma, INC. | $66.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $60.94 | 2023 | Camzyos |
| Inspire Medical Systems, INC. | $45.19 | 2023-2025 | Inspire |
| Janssen Biotech, INC. | $40.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $35.95 | 2019-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26.09 | 2025 | Cardiomems |
| Infobionic, INC | $21.53 | 2024 | Mome Device |
| Daiichi Sankyo INC. | $21.23 | 2023 | Injectafer |
| Lilly USA, LLC | $18.32 | 2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wuhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.